<DOC>
	<DOC>NCT00251082</DOC>
	<brief_summary>To demonstrate efficacy of continuous combined 0.5 mg estradiol and 2.5 mg dydrogesterone versus placebo in the treatment of vasomotor symptoms after a treatment period of 3 months and to investigate the bleeding pattern over a treatment period of one year</brief_summary>
	<brief_title>Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination</brief_title>
	<detailed_description />
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Nonhysterectomised postmenopausal women Amenorrhoea for &gt;= 12 months Serum estradiol and follicle stimulating hormone (FSH) in the postmenopausal range Known hypersensitivity to estradiol, dydrogesterone or any of the excipients of the study medication Baseline endometrial biopsy result other than described in the inclusion criteria (no endometrial tissue for diagnosis, hyperplasia, carcinoma). Insufficient endometrial tissue for diagnosis obtained at baseline biopsy and endometrial thickness &gt;= 5 mm (double layer) by transvaginal ultrasound. The presence of an endometrial polyp at baseline. Abnormal (uninvestigated and/or unexplained) vaginal bleeding in the last 12 months prior to Screening Visit (Visit 1). Estradiol pellet/implant therapy during the past 6 months. Previous systemic unopposed estrogen replacement therapy over 6 months or more. History or presence of malignant neoplasms other than basal or spinal cell carcinoma of the skin</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>hormone replacement</keyword>
	<keyword>vasomotoric symptoms</keyword>
	<keyword>bleeding pattern</keyword>
</DOC>